CoastWatcher
Moderator
A well designed study emerging from the Cleveland Clinic and published in Anesthesiology, September 2017, provides additional support for the proposition that testosterone replacement therapy is not a risk factor for cardiovascular events/cardiovascular mortality.
The authors conclude that "Preoperative testosterone is not associated with an increased incidence of a composite of postoperative in-hospital mortality and cardiovascular events."
The full text of this excellent article can be found here.
http://anesthesiology.pubs.asahq.org/article.aspx?articleid=2648831
- Nine hundred and forty seven patients on testosterone were matched to 4,598 non-testosterone patients.
- The incidence of in-hospital mortality was 1.3% in the testosterone group and 1.1% in the non-testosterone group
- The incidence of myocardial infarction was 0.2% in the testosterone group and 0.6% in the non-testosterone group.
- Similarly, no significant difference was found in stroke (testosterone vs. non-testosterone: 2.0% vs. 2.1%), pulmonary embolism (0.5% vs. 0.7%), or deep venous thrombosis (2.0% vs. 1.7%).
The authors conclude that "Preoperative testosterone is not associated with an increased incidence of a composite of postoperative in-hospital mortality and cardiovascular events."
The full text of this excellent article can be found here.
http://anesthesiology.pubs.asahq.org/article.aspx?articleid=2648831
